First CAR T-Cell Therapy Approved for Solid Tumors.

China approves satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors, for claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer.

• Why it matters: This approval marks a significant milestone in cancer treatment, addressing the challenge of developing effective CAR T-cell therapies for solid tumors, which have historically been difficult to treat.
• What they did: A phase II trial demonstrated that satricabtagene autoleucel increased progression-free survival and overall survival in patients with this specific cancer subtype.
• The result: The approval enables new treatment options for these patients but highlights the need for further research to enhance CAR T-cell effectiveness against solid tumors.